ClinicalTrials.gg
RecruitingNCT06676644influenzaUpdated Feb 24, 2026

Estimate the Safety and Effectiveness of Adjuvanted Influenza Vaccine Among Asian Elderly People When Compared to Non-adjuvanted Vaccines

An interventional study of adjuvanted and non-adjuvanted in Influenza Vaccines and Elderly, sponsored by National Taiwan University Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-02-24.

Sponsored by National Taiwan University Hospital · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Influenza, Human with a site in Taiwan — 6 open to participants now, 6 under way, 2 of them phase 3. Influenza, Human · Taiwan.

Planned enrollment
27th of 47
200 · median 300
Started
2024
with 4 others
No phase
7 of 52
2 open now
Registered
48th of 52
by date
Lead sponsor
5 of 52
National Taiwan University Hospital

Among the 52 studies in Influenza, Human with a site in Taiwan, this one is the 27th largest by planned enrollment of the 47 interventional ones that give a count, is one of 5 that started in 2024, is one of 7 with no phase, and was the 48th registered.

Influenza, Human

2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

6 of the 52 studies in Influenza, Human with a site in Taiwan are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Influenza, Human with a site in Taiwan, or all of them as a file.
02

Study summary

To compare the immunogenicity, cellular immune response, and safety between adjuvanted (aIIV4) and non-adjuvanted (IIV4) seasonal influenza vaccines in the Taiwanese elderly population with chronic medical conditions.

Read the detailed description

Annual influenza vaccination is the most important and cost-effective intervention in reducing the impact of influenza, and a key component of the WHO response and preparedness efforts for influenza of pandemic potential. Reduced effectiveness of conventional egg-based vaccination was observed among risk group, such as elderly and people on with chronic medical conditions, which may result from their impaired immunogenicity. WHO, as well as ACIP of the USA, Europe, and Australia suggested adjuvanted influenza vaccines as one of alternatives for those people, which could decrease the disease burden significantly in several analyses. An adjuvanted commercial vaccine has been approved in Taiwan recently, but the local data of safety and effectiveness analysis is limited. This 1-year randomized control trial is designed to estimate the safety and effectiveness of adjuvanted influenza vaccine among Asian elderly people when compared to non-adjuvanted vaccines.

03

Conditions studied

  • Influenza Vaccines
  • Elderly

Browse trials for

Keywords

  • influenza
  • adjuvanted vaccine
  • immunogenicity
  • elderly
  • safety
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 65 years or above
  • Presence of at least 1 chronic medical condition associated with increased risk of complicated influenza, including hypertension, (group A, B, E), asthma, congestive heart failure (ACC/AHA stage A, B, C, D), coronary arterial disease, diabetes mellitus, chronic liver disease ( score A, B, C) or chronic kidney disease (stage 1\~4), neuromuscular disorders, hematological or solid organ , recipient of hematopoietic stem cell transplantation or solid organ transplantation.

Exclusion criteria

Exclusion Criteria:

  • to influenza vaccination including history of severe adverse event after vaccination, such as anaphylaxis or Guillain-Barré Syndrome, or a severe bleeding tendency
  • Prior receipt of influenza vaccination during the current flu season.
  • Determination by the Principal Investigator (PI) that the participant is ineligible for enrollment based on clinical assessment.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    adjuvanted

    adjuvanted (aIIV4) influenza vaccine

    Drug: adjuvanted

  • Active comparator
    non-adjuvanted

    non-adjuvanted (IIV4) influenza vaccine

    Drug: non-adjuvanted

Interventions

  • Drugadjuvanted

    adjuvanted (aIIV4) influenza vaccine in the Taiwanses elderly with chronic medical conditions

  • Drugnon-adjuvanted

    non-adjuvanted (IIV4) influenza vaccine in the Taiwanses elderly with chronic medical conditions

06

What researchers measure

Primary outcomes

  1. The seroconversion rate (SCR) measured by the change in hemagglutination inhibition (HI) titer against the vaccine strains in serum between Day 1 (pre-vaccination) and Day 29.

    The seroconversion rate (SCR) measured by the change in hemagglutination inhibition (HI) titer against the vaccine strains in serum between Day 1 (pre-vaccination) and Day 29.

    Time frame: Measured through Day 29

Secondary outcomes

  1. The geometric mean titer (GMT), seroprotection rate (SPR), cellular immune responses on Day1, Day 29 (±3), Day 181 (±7), and Day 361 (±7)

    The geometric mean titer (GMT), seroprotection rate (SPR), cellular immune responses on Day1, Day 29 (±3), Day 181 (±7), and Day 361 (±7)

    Time frame: Measured through Day 361

  2. Incidence of severe adverse reactions within 28 days after immunization.

    Incidence of severe adverse reactions within 28 days after immunization.

    Time frame: Measured through Day 28

  3. Incidence of laboratory-confirmed influenza during the study period.

    Incidence of laboratory-confirmed influenza during the study period.

    Time frame: Measured through Day 361

  4. Incidence of emergency department visits and hospitalizations related to respiratory illness, all-cause mortality during the study period.

    Incidence of emergency department visits and hospitalizations related to respiratory illness, all-cause mortality during the study period.

    Time frame: Measured through Day 361

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Dec 2027, 37 months after the start.

Of 147 non-industry interventional studies with no phase under Influenza, Human, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 18. This study's planned 37 months is above that.

Counting every sponsor, half of 167 studies reached it within 6 months; a quarter within 3 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2024
First posted
Nov 6, 2024
StartActual
Nov 21, 2024
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Feb 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06676644
Responsible party
National Taiwan University Clinical Trial Center (Clinical professor, National Taiwan University Hospital) — Principal investigator
First posted
Nov 6, 2024
Start date
Nov 21, 2024
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Feb 24, 2026

Study contacts

Jann-Tay Wang Clinical Professor, M. D., Ph.D.
Contact
wangjt1124@ntuh.gov.tw
+886-2-2312-3456 ext. 263517
Un-In Wu Clinical Associate Professor, M. D.
Contact
uninwu@gmail.com
+886-2-2312-3456 ext. 265054

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion